The next generation of GLP-1 weight loss drugs

GLP-1 weight loss drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound have been on the market for a few years now. The medications are wildly popular, so it’s no surprise that other pharmaceutical companies like Pfizer and Amgen are trying to grab a piece of the market with similar drugs of their own. In this week’s STATus Report, we’ll see how several pharma companies are trying to compete with Novo and Lilly’s already safe and effective products. We’ll also learn what Novo and Lilly are cooking up in order to stay dominant in the weight loss marketplace. And I drop in for a visit with my STAT colleagues from “The Readout LOUD” podcast for their thoughts on this head-spinning GLP-1 news cycle. GLP-1 shots vs. pills, explained: https://youtu.be/ZYOdDiS4R50 Inside the world of internet peptides: https://youtu.be/xX7rWXK5ME0 0:00 Intro 0:49 ADA Scientific Sessions sets the stage 1:06 Pfizer's monthly shot via the Metsera acquisition 2:29 Boehringer Ingelheim's survodutide falls short 3:09 Oral pill race: Viking Therapeutics' VK2735 3:45 AstraZeneca's oral candidate + liver toxicity risks 4:27 Novo Nordisk's CagriSema 4:52 Eli Lilly's orforglipron and retatrutide 5:36 Research peptide warning 6:06 Dropping in on The Readout LOUD 9:36 Elaine's safety concerns on unleashing a powerful drug 11:02 Outro Novo Nordisk – Wegovy, Oral Wegovy (semaglutide pill), CagriSema Eli Lilly – Zepbound, Orforglipron, Retatrutide Pfizer – PF'3944 (MET-097i, via Metsera acquisition) Amgen – MariTide Boehringer Ingelheim – Survodutide Viking Therapeutics – VK2735 AstraZeneca – AZD5004 (licensed from Eccogene) More from STAT: Become a subscriber: https://www.statnews.com/stat-plus/ Watch Full Episodes: https://www.youtube.com/@Statnews Newsletters: https://www.statnews.com/signup/ STAT events: https://www.statnews.com/stat-events/ Facebook: https://www.facebook.com/statnews Twitter: https://twitter.com/statnews Instagram: https://www.instagram.com/status_report_ig/ Flipboard: rb.gy/3xnsxr STAT Reports: https://rb.gy/rexfwj STAT eBooks: https://rb.gy/eme3h5 ABOUT STAT: Founded in 2015, STAT is a global digital media brand that focuses on delivering fast, deep, and tough-minded journalism about the life sciences industries to over six million monthly site visitors and an additional 20 million readers on the Apple News app. STAT takes you inside academic labs, biotech boardrooms, and political backrooms, casting a critical eye on scientific discoveries, scrutinizing corporate strategies, and chronicling the roiling battles for talent, money, and market share. With an award-winning newsroom, STAT provides indispensable insights and exclusive stories on the technologies, personalities, power brokers, and political forces driving massive changes in the life sciences industry — and a revolution in human health.